Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 2/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7261252 | 0.74 | OPRD1 (0.33) | OPRD1SIGMAR1HTR2AKDM1ASLC6A4 | |
| SCHEMBL9615977 | 0.73 | SIGMAR1 (0.54) | OPRD1SIGMAR1 | |
| SCHEMBL28824800 | 0.73 | SIGMAR1 (0.36) | OPRD1SIGMAR1SLC6A4 | |
| SCHEMBL28600721 | 0.73 | SIGMAR1 (0.40) | OPRD1SIGMAR1 | |
| SCHEMBL9420013 | 0.73 | SIGMAR1 (0.36) | OPRD1SIGMAR1SLC6A4 | |
| SCHEMBL25129913 | 0.73 | SIGMAR1 (0.40) | OPRD1SIGMAR1SLC6A4 | |
| SCHEMBL2619379 | 0.73 | HTR2A (0.41) | SIGMAR1HTR2ASLC6A4 | |
| SCHEMBL30869312 | 0.73 | HTR2A (0.41) | SIGMAR1HTR2ASLC6A4 | |
| SCHEMBL28492898 | 0.71 | HTR2A (0.44) | OPRD1SIGMAR1HTR2AMAOBSLC6A4 | |
| SCHEMBL7912523 | 0.71 | SIGMAR1 (0.36) | OPRD1SIGMAR1SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1641730-B1 | RECOMBINED MOLECULES AND PREPARATION THEREOF | VALENT TECHNOLOGIES LLC (US) | 2014-07-30 | — | — | EP | claimed |
| US-20110312034-A1 | Recombined Molecules and Preparation Thereof | Valent Technologies | 2011-12-22 | — | — | US | claimed |
| EP-1641730-A1 | RECOMBINED MOLECULES AND PREPARATION THEREOF | Valent Technologies LLC (US) | 2006-04-05 | — | — | EP | claimed |
| WO-2005016851-A1 | RECOMBINED MOLECULES AND PREPARATION THEREOF | VALENT TECHNOLOGIES, LLC (US) | 2005-02-24 | — | — | WO | claimed |
| US-20050010029-A1 | Recombined molecules and preparation thereof | VALENT TECHNOLOGIES LLC | 2005-01-13 | — | — | US | claimed |
| US-10138264-B2 | Recombined molecules and preparation thereof | VALENT TECHNOLOGIES LLC (US) | 2018-11-27 | — | — | US | disclosed |
| EP-1641730-B1 | RECOMBINED MOLECULES AND PREPARATION THEREOF | VALENT TECHNOLOGIES LLC (US) | 2014-07-30 | — | — | EP | disclosed |
| US-20110312034-A1 | Recombined Molecules and Preparation Thereof | Valent Technologies | 2011-12-22 | — | — | US | disclosed |
| EP-1641730-A1 | RECOMBINED MOLECULES AND PREPARATION THEREOF | Valent Technologies LLC (US) | 2006-04-05 | — | — | EP | disclosed |
| WO-2005016851-A1 | RECOMBINED MOLECULES AND PREPARATION THEREOF | VALENT TECHNOLOGIES, LLC (US) | 2005-02-24 | — | — | WO | disclosed |
| US-20050010029-A1 | Recombined molecules and preparation thereof | VALENT TECHNOLOGIES LLC | 2005-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10138264-B2 | Recombined molecules and preparation thereof | MRPL21, RCE1, FURIN | OPRD1 3773/4885SIGMAR1 4521/4885HTR2A 4598/4885 |
| US-20050010029-A1 | Recombined molecules and preparation thereof | MRPL21, RCE1, FURIN | OPRD1 3773/4885SIGMAR1 4521/4885HTR2A 4598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.